1160653-95-1

Basic information

• Product Name: 3-bromo-2-fluoro-6-hydroxybenzaldehyde
• Synonyms: 3-bromo-2-fluoro-6-hydroxybenzaldehyde
• CAS NO: 1160653-95-1
• Molecular Formula: C₇H₄BrFO₂
• Molecular Weight: 219.0078632
• Mol File: 1160653-95-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-bromo-2-fluoro-6-hydroxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-2-fluoro-6-hydroxybenzaldehyde(1160653-95-1)
• EPA Substance Registry System: 3-bromo-2-fluoro-6-hydroxybenzaldehyde(1160653-95-1)

Safety Data

• Hazardous Substances Data: 1160653-95-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
3-bromo-2-fluoro-6-hydroxybenzaldehyde is utilized as an intermediate in the synthesis of various drugs and organic compounds. Its unique functional groups and reactivity make it a promising building block for the development of new pharmaceuticals.
Used in Agrochemical Development:
In addition to pharmaceuticals, 3-bromo-2-fluoro-6-hydroxybenzaldehyde also serves as a key intermediate in the creation of agrochemicals. Its potential in this field is attributed to its ability to be a part of the synthesis process for new and effective agricultural products.

Upstream product

• 1160653-94-0 3-bromo-2-fluoro-6-methoxybenzaldehyde 
• 458-50-4 1-bromo-2-fluoro-4-methoxybenzene 
• 149947-15-9 3-bromo-2-fluorobenzaldehyde 

Relevant articles and documents

METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY

Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein.

FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV

The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising thes

Pd-Catalyzed Ortho C-H Hydroxylation of Benzaldehydes Using a Transient Directing Group

The direct Pd-catalyzed ortho C-H hydroxylation of benzaldehydes was achieved using 4-chloroanthranilic acid as the transient directing group, 1-fluoro-2,4,6-trimethylpyridnium triflate as the bystanding oxidant, and p-toluenesulfonic acid as the putative oxygen nucleophile. The unusual C-H chlorination and polyfluoroalkoxylation reactions signaled the importance of external nucleophiles to the outcome of Pd(IV) reductive eliminations.

IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

SPIROINDOLINONE DERIVATIVES

There are provided compounds of the formula and pharmaceutically acceptable salts and esters thereof wherein W, V, X, Y, A, R and R' are as described herein. The compounds are useful as anticancer agents.